title: Prolactin inhibition at mid-lactation influences adiposity and thyroid function in adult rats.
abstract: Maternal hypoprolactinemia at the end of lactation (a precocious weaning model) increases milk leptin transfer and results in overweight, leptin resistance, and secondary hypothyroidism at adulthood. We studied the effects of prolactin (PRL) inhibition during mid-lactation (a partial malnutrition model) on milk leptin transfer, leptinemia, body composition, and thyroid function. Lactating rats were treated with bromocryptine (BRO, 1 mg/twice daily) or saline on days 7, 8, and 9 of lactation. Offspring were sacrificed 10, 21, and 90 days after birth. After treatment, BRO-treated dams showed hypoprolactinemia and hyperleptinemia, and produced less milk with lower levels of lactose and higher milk triglycerides. Milk leptin levels were lower at weaning. Offspring of BRO-treated dams had lower body weight and length as well as less visceral fat during lactation and adulthood. Total fat was also lower at weaning and adult life, whereas total protein was higher at 90 days-old. BRO offspring presented lower serum T4 and TSH at 10 days-old and weaning, respectively. When adults, these rats exhibited hypoleptinemia, lower levels of thyroid hormones, and higher TSH. Early inhibition of PRL therefore leads to offspring malnutrition and affects subsequent growth. Also, inhibition of PRL during lactation predisposes offspring to hypothyroidism; however, when the inhibition occurs during late lactation, the hypothyroidism is secondary, whereas when it is restricted to mid-lactation, the thyroid hypofunction is primary. The programming effect of milk suppression thus depends on the developmental stage of offspring.
authors.affiliation: Department of Physiological Sciences, Roberto Alcantara Gomes Biology Institute, State University of Rio de Janeiro, Rio de Janeiro, Brazil. pclisboa@uerj.br
authors.forename: P C
authors.initials: PC
authors.lastname: Lisboa
authors.forename: L
authors.initials: L
authors.lastname: Pires
authors.forename: E
authors.initials: E
authors.lastname: de Oliveira
authors.forename: N S
authors.initials: NS
authors.lastname: Lima
authors.forename: I T
authors.initials: IT
authors.lastname: Bonomo
authors.forename: A M
authors.initials: AM
authors.lastname: Reis
authors.forename: M C F
authors.initials: MC
authors.lastname: Passos
authors.forename: E G
authors.initials: EG
authors.lastname: Moura
mesh_terms: D050154:Adiposity / Q000187:drug effects* / Q000502:physiology; D000375:Aging / Q000502:physiology; D000818:Animals; D001971:Bromocriptine / Q000494:pharmacology*; D005247:Feeding Behavior / Q000187:drug effects; D005260:Female; D007037:Hypothyroidism / Q000139:chemically induced / Q000503:physiopathology; D007774:Lactation / Q000502:physiology*; D020738:Leptin / Q000097:blood; D044342:Malnutrition / Q000209:etiology; D008892:Milk / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D009765:Obesity / Q000097:blood / Q000503:physiopathology; D011388:Prolactin / Q000037:antagonists & inhibitors* / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D013961:Thyroid Gland / Q000187:drug effects* / Q000502:physiology*; D015430:Weight Gain / Q000187:drug effects
chemical_list: D020738:Leptin; D001971:Bromocriptine; D011388:Prolactin